The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Examining Bias in Studies of Statin Treatment and Survival in Patients With Cancer
Open accessAbstract
IMPORTANCE: Patients with cancer who use statins appear to have a substantially better survival than nonusers in observational studies. However, this inverse association between statin use and mortality may be due to selection bias and immortal-time bias. OBJECTIVE: To emulate a randomized trial of statin therapy initiation that is free of selection bias and immortal-time bias. DESIGN, SETTING, AND PARTICIPANTS: We used observational data on 17 372 patients with cancer from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database (2007-2009) with complete follow-up until 2011. The SEER-Medicare database links 17 US cancer registries and claims files from Medicare and Medicaid in 12 US states. We included individuals with a new diagnosis of colorectal, breast, prostate, or bladder cancer who had not been prescribed statins for at least 6 months before the cancer diagnosis. Individuals were duplicated, and each replicate was assigned to either the strategy "statin therapy initiation within 6 months after diagnosis" or "no statin therapy initiation." Replicates were censored when they stopped following their assigned strategy, and the potential selection bias was adjusted for via inverse-probability weighting. Hazard ratios (HRs), cumulative incidences, and risk differences were calculated for all-cause mortality and cancer-specific mortality. We then compared our estimates with those obtained using the same analytic approaches used in previous observational studies. EXPOSURES: Statin therapy initiation within 6 months after cancer diagnosis. MAIN OUTCOMES AND MEASURES: Cancer-specific and all-cause mortality using SEER-Medicare data and data from previous studies. RESULTS: Of the 17 372 patients whose data were analyzed, 8440 (49%) were men, and 8932 (51%) were women (mean [SD] age, 76.4 [7.4] years; range, 66-115 years). The adjusted HR (95% CI) comparing statin therapy initiation vs no initiation was 1.00 (0.88-1.15) for cancer-specific mortality and 1.07 (0.93-1.21) for overall mortality. Cumulative incidence curves for both groups were almost overlapping (the risk difference never exceeded 0.8%). In contrast, the methods used by prior studies resulted in an inverse association between statin use and mortality (pooled hazard ratio 0.69). CONCLUSION AND RELEVANCE: After using methods that are not susceptible to selection bias from prevalent users and to immortal time bias, we found that initiation of therapy with statins within 6 months after cancer diagnosis did not appear to improve 3-year cancer-specific or overall survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hernán, M. A., Sauer, B. C., Hernández-Díaz, S., Platt, R., & Shrier, I. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2016.04.014 · Cited by 1,097 · cited 1×
“Patients From the SEER-Medicare Database There were 17 372 eligible individuals (Figure 1) with a median (interquartile range) of 33 (25-42) months of follow-up for all-cause mortality (maximum follow-up, 52 months) and 23 (15-31) months for cancer-specific mortality (maximum follow-up, 39 months).”
Self-citation
Cited by
Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention
Butler, L. M., Perone, Y., Dehairs, J., Lupien, L. E., de Laat, V., Talebi, A., Loda, M., Kinlaw, W. B., & Swinnen, J. V. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.013 · Cited by 589
Gupta, S., Wang, W., Hayek, S. S., Chan, L., Mathews, K. S., Melamed, M. L., Brenner, S. K., Leonberg-Yoo, A., Schenck, E. J., Radbel, J., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.6252 · Cited by 535
Self-citationTargeting cancer-promoting inflammation — have anti-inflammatory therapies come of age?
Hou, J., Karin, M., & Sun, B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00459-9 · Cited by 366
Qiao, Y., Shin, J.-I., Chen, T. K., Inker, L. A., Coresh, J., Alexander, G. C., Jackson, J. W., Chang, A. R., & Grams, M. E. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.0193 · Cited by 199
Association of statin use with clinical outcomes in patients with triple‐negative breast cancer
Nowakowska, M. K., Lei, X., Thompson, M. T., Shaitelman, S. F., Wehner, M. R., Woodward, W. A., Giordano, S. H., & Nead, K. T. (2021) · Cancer · doi:10.1002/cncr.33797 · Cited by 62
“It has been suggested that the observed associations between statin use and improved cancer outcomes may be a false positive secondary to limitations in methodology, specifically the introduction of immortal time bias and selection bias.(48) Immortal time bias can occur in pharmacoepidemiology studies when determinati…”
Background
Metadata
- Authors
- Emilsson, L., García-Albéniz, X., Logan, R. W., Caniglia, E. C., Kalager, M., & Hernán, M. A.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2018-01-01
- Volume
- 4
- Issue
- 1
- Pages
- 63
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2749616207
- Cited by
- 188
- References
- 1
- FWCI
- 3.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Examining Bias in Studies of Statin Treatment and Survival in Patients With Cancer. https://app.cochat.ai/papers/10.1001/jamaoncol.2017.2752
- The paper
- Emilsson, L., García-Albéniz, X., Logan, R. W., Caniglia, E. C., Kalager, M., & Hernán, M. A. (2018). Examining Bias in Studies of Statin Treatment and Survival in Patients With Cancer. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2017.2752
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.